Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 December 2020Website:
http://www.synaptogen.comNext earnings report:
15 May 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:17:36 GMTDividend
Analysts recommendations
Institutional Ownership
What type of business is Synaptogenix?
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was incorporated in 2012 and is headquartered in New York, New York.
What sector is Synaptogenix in?
Synaptogenix is in the Healthcare sector
What industry is Synaptogenix in?
Synaptogenix is in the Biotechnology industry
What country is Synaptogenix from?
Synaptogenix is headquartered in United States
When did Synaptogenix go public?
Synaptogenix initial public offering (IPO) was on 08 December 2020
What is Synaptogenix website?
https://www.synaptogen.com
Is Synaptogenix in the S&P 500?
No, Synaptogenix is not included in the S&P 500 index
Is Synaptogenix in the NASDAQ 100?
No, Synaptogenix is not included in the NASDAQ 100 index
Is Synaptogenix in the Dow Jones?
No, Synaptogenix is not included in the Dow Jones index
When was Synaptogenix the previous earnings report?
No data
When does Synaptogenix earnings report?
The next expected earnings date for Synaptogenix is 15 May 2025